Markedly enhanced levodopa pharmacokinetics from continuous subcutaneous carbidopa administration

被引：0
|
作者：
Yacoby-Zeevi, O. [1 ]
Oren, S. [1 ]
LeWitt, P. [2 ,3 ]
机构：
[1] NeuroDerm Ltd, Ness Ziona, Israel
[2] Wayne State Univ, Sch Med, Southfield, MI USA
[3] Henry Ford Hosp, Southfield, MI USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics-pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612
    Birnberg, T.
    Adar, L.
    Poewe, W.
    Nyholm, D.
    Bjornsson, M.
    Karlsson, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 608 - 608
  • [22] The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
    K. Jorga
    Barbel Fotteler
    Greg Sedek
    Thorkild Nielsen
    John Aitken
    Journal of Neurology, 1998, 245 : 223 - 230
  • [23] The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
    Jorga, K
    Fotteler, B
    Sedek, G
    Nielsen, T
    Aitken, J
    JOURNAL OF NEUROLOGY, 1998, 245 (04) : 223 - 230
  • [24] Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers
    Nyholm, D.
    Ehrnebo, M.
    Lewander, T.
    Trolin, C. G.
    Backstrom, T.
    Panagiotidis, G.
    Spira, J.
    Nystrom, C.
    Aquilonius, S. -M.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 127 (02): : 124 - 132
  • [25] Pharmacokinetics of levodopa/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson's disease
    Rosebraugh, M.
    Kym, P.
    Liu, W.
    Facheris, M.
    Benesh, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 838 - 838
  • [26] Transcutaneous Port for Continuous Duodenal Levodopa/Carbidopa Administration in Parkinson's Disease
    Meppelink, Anne Marthe
    Nyman, Rickard
    van Laar, Teus
    Drent, Martje
    Prins, Ted
    Leenders, Klaus Leonhard
    MOVEMENT DISORDERS, 2011, 26 (02) : 331 - 334
  • [27] Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
    Othman, Ahmed A.
    Rosebraugh, Matthew
    Chatamra, Krai
    Locke, Charles
    Dutta, Sandeep
    JOURNAL OF PARKINSONS DISEASE, 2017, 7 (02) : 275 - 278
  • [28] Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
    Birnberg, T.
    Smania, G.
    Bjornsson, M.
    Jonsson, N.
    Case, R.
    Oren, S.
    Adar, L.
    Karlsson, M.
    MOVEMENT DISORDERS, 2020, 35 : S389 - S389
  • [29] Quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study
    Espay, Alberto
    Yardeni, Tami
    Adar, Liat
    Case, Ryan
    Poewe, Werner
    Isaacson, Stuart
    MOVEMENT DISORDERS, 2023, 38 : S16 - S16
  • [30] Pharmacokinetics and safety of concurrent donepezil HCl and levodopa/carbidopa administration in subjects with Parkinson's disease
    Okereke, CS
    Kumar, D
    Cullen, EI
    Pratt, RD
    Hahne, WF
    NEUROLOGY, 2001, 56 (08) : A457 - A457
12345